PHARMOS BEGIN PATIENT DOSING IN PAIN MEDICATION TRIAL

A A

Pharmos has begun patient dosing for its Phase IIa clinical study of cannabinor or PRS-211,375, a CB2-synthetic cannabinoid drug candidate, for treatment of pain.

The company expects to complete the trial in the third quarter of 2006 and indicated the treatment of three patients since the receipt of approval to commence the study in UK. The trial is a single-center, randomized, double-blinded, single-dose intravenous consisting of 100 healthy male subjects, and would include safety and analgesic efficacy of different cannabinor doses compared with placebo for acute pain following extraction of mandibular third molar teeth.